{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Immatics NV Hits Day High with 10.2% Surge Amid Strong Intraday Performance
Immatics NV, a small-cap biotechnology firm, experienced a notable stock surge today, contrasting with a slight decline in the S&P 500. Despite recent gains over the past week and month, the company faces longer-term challenges, including negative EBITDA and a market capitalization of USD 706 million.
Immatics NV Experiences Revision in Stock Evaluation Amid Mixed Market Indicators
Immatics NV, a small-cap biotechnology firm, has seen its stock price slightly decrease to $9.39, following a year marked by significant volatility. The company has outperformed the S&P 500 in recent weeks and months, but longer-term performance reveals challenges compared to broader market trends.
Is Immatics NV technically bullish or bearish?
As of October 3, 2025, Immatics NV's trend has shifted to bullish, with strong short-term performance outpacing the S&P 500, though it has underperformed over longer periods.
Is Immatics NV technically bullish or bearish?
As of October 3, 2025, Immatics NV's technical trend is bullish, supported by positive indicators like a bullish MACD and Bollinger Bands, although it has underperformed over the past year and three years compared to the S&P 500.
Immatics NV Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Immatics NV, a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly to $6.70. Despite a challenging year with a -44.90% return, recent performance shows improvement, with notable gains over the past week and month, suggesting potential for recovery amid mixed technical indicators.
Is Immatics NV technically bullish or bearish?
As of August 11, 2025, Immatics NV shows a mildly bullish technical trend, supported by bullish daily moving averages and weekly MACD, despite mixed signals from KST and Dow Theory, while it has outperformed the S&P 500 recently but underperformed over the past year.
Is Immatics NV overvalued or undervalued?
As of May 13, 2025, Immatics NV is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 1.25 and an unfavorable EV to EBITDA ratio of -2.77, alongside a year-to-date stock return of -23.77% compared to a 2.44% gain in the S&P 500.
Is Immatics NV technically bullish or bearish?
As of June 18, 2025, Immatics NV shows a mildly bearish trend, indicated by daily moving averages and weekly Dow Theory, despite mixed signals from the MACD and a neutral RSI on the weekly timeframe.
What does Immatics NV do?
Immatics NV is a clinical-stage biopharmaceutical company focused on developing T-Cell receptors for targeted cancer therapies. As of March 2025, it has a market cap of $746.32 million, with net sales of $20 million and a net loss of $42 million.
How big is Immatics NV?
As of Jun 18, Immatics NV has a market capitalization of 746.32 million, with net sales of 155.29 million and a net profit of -22.90 million over the latest four quarters. Shareholder's funds are 595.25 million, and total assets amount to 720.86 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
